Want to see MED full AI Analyst Report?
MED Stock Chart & Stats
$10.97
-$0.62(-3.78%)
At close: 4:00 PM EST
$10.97
-$0.62(-3.78%)
Day’s Range― - ―
52-Week Range$9.22 - $15.37
Previous CloseN/A
Volume160.90K
Average Volume (3M)183.09K
Market Cap
$122.64M
Enterprise Value$69.66M
Total Cash (Recent Filing)$168.95M
Total Debt (Recent Filing)$16.10M
Price to Earnings (P/E)―
Beta0.83
Next Earnings
Aug 10, 2026EPS Estimate
-0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.82
Shares Outstanding11,119,115
10 Day Avg. Volume175,854
30 Day Avg. Volume183,095
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.59
Price to Sales (P/S)0.30
P/FCF Ratio93.90
Enterprise Value/Market Cap0.57
Enterprise Value/Revenue0.20
Enterprise Value/Gross Profit0.29
Enterprise Value/Ebitda10.99
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.03
Revenue Forecast (FY)$273.70M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthA large cash position and negligible debt give Medifast durable financial flexibility over the next several quarters. That runway supports the product rollout, funding for coach incentives and marketing, and absorps execution risk while the company rightsizes operations and pursues profitability.
Coach Productivity GainsRising revenue per coach shows improving monetization of the core DTC coach channel, meaning the company can extract more revenue from a smaller field. Sustained productivity gains improve unit economics, lower required reinvestment per sale, and are a structural lead indicator for eventual revenue and margin recovery.
Structural Cost ReductionsMeaningful and planned SG&A savings indicate management is addressing the cost base to restore operating leverage. If sustained, these permanent cost reductions can materially improve margins and reduce the revenue level needed to reach profitability, improving the balance between scale and profitably over the medium term.
Bears Say
Material Revenue DeclineA steep top-line contraction erodes scale advantages and drives leverage losses across gross margin and SG&A. Multi-quarter revenue declines have already produced negative operating and net margins and turned free cash flow negative, making sustainable profitability dependent on revenue recovery or continued structural cost cuts.
Coach Network ContractionThe independent coach network is the company's primary distribution engine; a near-45% decline materially reduces customer acquisition, recurring order flow, and referral-driven growth. Rebuilding coach counts is time-consuming and costly, leaving persistent revenue and retention risk until the field stabilizes and re-expands.
Dependence On Product Launch & GLP-1 HeadwindRecovery is contingent on successful adoption of a new metabolic product and competing against structural market disruption from GLP-1 drugs. This creates a single-point execution risk: delayed or weaker adoption would postpone profitability, worsen cash conversion, and force deeper structural changes to the business model.
Medifast News
MED FAQ
What was Medifast’s price range in the past 12 months?
Medifast lowest stock price was $9.22 and its highest was $15.37 in the past 12 months.
What is Medifast’s market cap?
Medifast’s market cap is $122.64M.
When is Medifast’s upcoming earnings report date?
Medifast’s upcoming earnings report date is Aug 10, 2026 which is in 26 days.
How were Medifast’s earnings last quarter?
Medifast released its earnings results on May 04, 2026. The company reported -$0.19 earnings per share for the quarter, beating the consensus estimate of -$0.52 by $0.33.
Is Medifast overvalued?
According to Wall Street analysts Medifast’s price is currently Overvalued.
Does Medifast pay dividends?
Medifast pays a Quarterly dividend of $1.65 which represents an annual dividend yield of N/A. See more information on Medifast dividends here
What is Medifast’s EPS estimate?
Medifast’s EPS estimate is -0.65.
How many shares outstanding does Medifast have?
Medifast has 11,119,115 shares outstanding.
What happened to Medifast’s price movement after its last earnings report?
Medifast reported an EPS of -$0.19 in its last earnings report, beating expectations of -$0.52. Following the earnings report the stock price went up 22.484%.
Which hedge fund is a major shareholder of Medifast?
Currently, no hedge funds are holding shares in MED
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Medifast Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
MED Sentiment 67%
Sector Average 64%
Sector Average 64%
Hedge Fund Trend
Decreased
By 294.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $63.0K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.03%
12-Months-Change
Fundamentals
Return on Equity
-9.68%
Trailing 12-Months
Asset Growth
-9.99%
Trailing 12-Months
Company Description
Medifast
Medifast, Inc., through its various divisions, develops and provides a range of consumable health and nutritional items tailored for weight loss, weight management, and general wellness. These products are distributed across the United States and the Asia-Pacific region. Their extensive portfolio encompasses snack bars, savory bites, cereals, drinks, substantial meal choices, oatmeal, pancakes, puddings, soft serves, shakes, smoothies, baked goods, and soups. These offerings are marketed under proprietary brands like OPTAVIA, Optimal Health by Take Shape for Life, and Flavors of Home. The company facilitates sales primarily through direct e-commerce transactions. Established in 1980, Medifast, Inc. maintains its corporate headquarters in Baltimore, Maryland.
Technical Analysis
Ownership Overview
5.36% Insiders
14.59% Mutual Funds
0.40% Other Institutional Investors
65.94% Public Companies and
Individual Investors